Engineered Antibody Fragments For The Diagnosis And Treatment Of Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$196,886.00
Summary
We plan to investigate the use of genetically-engineered antibody fragments in the diagnosis and treatment of clinically-important human eye diseases. The work will be carried out in experimental models, but the goal is to develop a new class of drugs that will be widely applicable in human inflammatory eye disease and eye infections. Antibodies are natural proteins, found in blood and body secretions, that protect humans from infections. However, they can be made in the laboratory and monoclona ....We plan to investigate the use of genetically-engineered antibody fragments in the diagnosis and treatment of clinically-important human eye diseases. The work will be carried out in experimental models, but the goal is to develop a new class of drugs that will be widely applicable in human inflammatory eye disease and eye infections. Antibodies are natural proteins, found in blood and body secretions, that protect humans from infections. However, they can be made in the laboratory and monoclonal antibodies in particular - those with a single defined specificity - have found widespread use in many medical applications. For the past 15 years, monoclonal antibodies have been used therapeutically, that is, they have been administered to humans to treat some diseases. Antibodies are big proteins that have multiple functions. Their very size and the multiplicity of their actions prevent their use in some therapeutic situations. In recent years, advances in genetic engineering and biotechnology have developed to the extent that small fragments of monoclonal antibodies can be produced in the laboratory with relative ease. Such fragments should have very substantial advantages over intact antibodies in the diagnosis and treatment of human eye disease. Engineered antibody fragments hold enormous potential for ophthalmic use, especially if they can be administered topically as eye-drops. In this project, we aim to determine whether antibody fragments can be used in the diagnosis and the treatment of four potentially blinding conditions: acute anterior uveitis and corneal graft rejection, which are inflammatory eye diseases, and herpetic keratitis and Acanthamoeba keratitis, which are eye infections.Read moreRead less
Stability Engineering Of Human Antibody Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$421,104.00
Summary
Therapeutic monoclonal antibodies are among the fastest growing class of drugs with more than $30 billion sales in 2011. Unfortunately, antibodies often display limited stability and a tendency to aggregate. This greatly hinders their development and results in high failure rates of otherwise promising candidates. We have recently identified mutations that render human antibodies resistant to aggregation. Here we apply this technology to a monoclonal antibody candidate developed by a leading pha ....Therapeutic monoclonal antibodies are among the fastest growing class of drugs with more than $30 billion sales in 2011. Unfortunately, antibodies often display limited stability and a tendency to aggregate. This greatly hinders their development and results in high failure rates of otherwise promising candidates. We have recently identified mutations that render human antibodies resistant to aggregation. Here we apply this technology to a monoclonal antibody candidate developed by a leading pharmaceutical company.Read moreRead less
Heparin Induced Thrombocytopenia (HIT): Further Characterization Of Disease Mechanism Will Improve Patient Treatment
Funder
National Health and Medical Research Council
Funding Amount
$456,484.00
Summary
Thrombus formation occurs as a side effect of heparin treatment in many patients. This condition is called Heparin Induced Thrombocytopenia (HIT). The clots may be stabilised by secretions from cells called neutrophils. In this project we will study this possibility using a mouse model of HIT and will explore therapeutic approaches to inhibit clot stabilisation.
Monoclonal antibodies, such as the breast cancer therapeutic Herceptin, have revolutionised the treatment of cancer and inflammatory conditions. Will over $30 billion sales in 2011, they have also spawned a growing biotech industry. We have a generated a highly specific monoclonal antibody, which has shown efficacy in models of disease. This project will further advance and develop this monoclonal, allowing us to initiate clinical studies in patients.
New Therapies Requiring Ultra Large Scale Monoclonal Ab Production In Microalgae
Funder
National Health and Medical Research Council
Funding Amount
$630,089.00
Summary
Monoclonal antibodies target pathogens and molecules with exquisite specificity, and are essential for therapeutics and diagnostics. They are currently made using high-tech/limited-capacity mammalian cell cultures which limit them to low-dose applications. We aim to enable new, high-dose antibody therapies (e.g. antiviral treatments, passive immunisation) via rapid, low-cost, dramatically larger-scale production of valuable medicinal antibodies in a photosynthetic-driven, green algae system.
SIGN Receptors And The Antiinflammatory Activity Of Sialylated IgG Fcs
Funder
National Health and Medical Research Council
Summary
IgG antibodies are a crucial component of the immune system, and significantly contribute to host protection against cancer and infectious diseases. Additionally, therapeutic IgG antibodies have been developed for treatment of cancer and inflammatory diseases. The studies proposed herein will elucidate one important aspect of how IgG antibodies act as anti-inflammatory agents, and may lead to the design of more effective IgG based therapies for the treatment of inflammatory diseases or cancer.
Monoclonal antibodies, such as the cancer therapeutic Pembrolizumab, have revolutionised the treatment of cancer and many inflammatory conditions. With over $100 billion in sales in 2018, they also underpin a growing biotech industry. We have developed a highly specific, high affinity therapeutic antibody candidate, and demonstrated efficacy in animal models of malignancy. This project will advance and develop this monoclonal, allowing us to initiate clinical studies in patients.